OHSS Prevention: How Modern IVF Protocols Keep You Safe

Ovarian hyperstimulation syndrome used to be one of IVF's most feared complications — severe cases meant hospitalization, fluid drainage, blood clots, and occasionally life-threatening outcomes. In 2026, severe OHSS is largely preventable. The combination of GnRH agonist triggers, individualized dosing, and freeze-all strategies has transformed OHSS from an accepted risk into a protocol-design failure. Understanding these safeguards helps you evaluate any clinic you're considering — including those in Colombia.

What Is OHSS?

OHSS occurs when ovaries over-respond to gonadotropin stimulation, producing an excessive number of follicles. The syndrome involves fluid leaking from overstimulated ovarian blood vessels into the abdominal cavity and sometimes the chest. Symptoms range from mild bloating and discomfort (which is normal and expected after any stimulation) to severe fluid accumulation, electrolyte imbalance, blood clotting disorders, and kidney compromise.

Mild OHSS symptoms — bloating, mild abdominal discomfort, slight weight gain — affect many patients undergoing stimulation and generally resolve within a week. The clinical concern is moderate-to-severe OHSS, which can require hospitalization and, in rare cases, poses serious health risks.

Who's at Risk

Certain patient profiles carry higher OHSS risk. Clinics should screen for these factors before selecting your stimulation protocol:

• High AMH levels (above 3.5–5.0 ng/mL) — indicates a large antral follicle pool that may hyper-respond
• Polycystic ovary syndrome (PCOS) — the single strongest risk factor
• Young age (under 30) — larger ovarian reserve
• Low BMI — lower body mass concentrates circulating hormones
• Previous OHSS episode — the strongest predictor of recurrence
• High follicle count during stimulation (>15 follicles over 10mm)

Prevention Strategies

Modern OHSS prevention is layered — no single measure alone eliminates risk, but combining strategies reduces severe OHSS to near zero:

Individualized starting doses: Rather than a one-size-fits-all gonadotropin dose, clinics use AMH levels, antral follicle count, BMI, and age to calculate a starting dose. High-risk patients start on lower doses (often 100–150 IU) and adjust based on response.

Antagonist protocol: The GnRH antagonist protocol has become standard for high-risk patients because it allows the use of a GnRH agonist trigger (explained below) — the single most important OHSS prevention tool. Older long-agonist (Lupron down-regulation) protocols lock you into an hCG trigger, which is the primary OHSS driver.

Coasting: If estradiol levels rise too rapidly during stimulation, the clinic may withhold gonadotropins for 1–3 days (coasting) to let smaller follicles regress before triggering. This is an older technique that's less relied upon now that better tools exist, but remains a useful safety valve.

Dopamine agonists: Cabergoline, a dopamine receptor agonist, reduces vascular permeability (the fluid leakage that causes OHSS symptoms) and is sometimes prescribed for 7–10 days starting on the day of retrieval for at-risk patients.

The Trigger Revolution

The most impactful advance in OHSS prevention is the switch from hCG triggers to GnRH agonist triggers in high-risk patients. Here's why:

hCG (human chorionic gonadotropin) triggers final egg maturation but also stimulates the ovaries for 7–10 days due to its long half-life. In hyper-responding patients, this prolonged stimulation is what tips mild bloating into moderate-severe OHSS.

GnRH agonist triggers (such as Lupron/leuprolide) work differently — they cause a surge of the body's own LH, which has a much shorter half-life (24–36 hours vs. 7–10 days). The ovaries mature the eggs but then quiet down quickly, virtually eliminating the late-onset OHSS that hCG causes.

Freeze-All as Safety Net

The GnRH agonist trigger works best with a freeze-all strategy — vitrifying all embryos and transferring in a subsequent cycle. This is because the agonist trigger doesn't support a robust luteal phase the way hCG does, making fresh transfers less reliable. But freeze-all is independently a safety net: pregnancy itself produces hCG, which can trigger or worsen OHSS after a fresh transfer. Separating retrieval from transfer eliminates pregnancy-related OHSS entirely.

For medical travelers to Colombia, freeze-all is often the default approach anyway — it allows you to complete your stimulation and retrieval trip, return home, and come back for a shorter FET trip once your body has recovered and embryo testing results are in.

OHSS Prevention at Colombian Clinics

Colombia's leading fertility clinics within JCI-accredited hospital systems have adopted modern OHSS-prevention protocols including antagonist protocols with agonist triggers, individualized dosing, and freeze-all for high responders. When evaluating a Colombian clinic, ask specifically about their OHSS-prevention approach — the answers should align with the strategies outlined above.

The country's healthcare system, ranked #22 globally by the WHO (2000 report), provides the hospital-level infrastructure to manage the rare case of severe OHSS that breaks through prevention measures — IV fluid management, paracentesis (fluid drainage), and inpatient monitoring are available at JCI-accredited facilities in Medellín, Bogotá, and Cali.

Explore Our Colombia Medical Network